Brought to you by 
Guardant Health expands Guardant360 availability with $50mm in Series C funds
04 Feb 2015
Executive Summary
Guardant Health Inc. (oncology diagnostics) raised $50mm through its Series C round. Lightspeed Venture Partners led and was joined by Formation 8 and returning backers Khosla Ventures and Sequoia Capital. Proceeds will help the company expand the availability of its Guardant360 biopsy-free test, which identifies tumor genomic alterations through a blood sample to help physicians plan appropriate therapies for specific patients. Guardant has now raised just under $100mm to date.
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Guardant Health expands Guardant360 availability with $50mm in Series C funds
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice